Since the introduction of the direct oral anticoagulants (DOACs) into clinical practice, they have been increasingly prescribed for the management of atrial fibrillation. Among the DOACs, apixaban has been used most frequently in the chronic kidney disease (CKD) population primarily owing to its favorable pharmacokinetic profile. Importantly, a steady stream of evidence consistently demonstrates apixaban’s superior efficacy for stroke prevention and improved safety (ie, a decreased risk of bleeding) among individuals with atrial fibrillation and CKD, as compared to vitamin K antagonists (VKAs).